GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Truscreen Group Ltd (NZSE:TRU) » Definitions » PB Ratio

Truscreen Group (NZSE:TRU) PB Ratio : 3.00 (As of Jun. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Truscreen Group PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-06-13), Truscreen Group's share price is NZ$0.018. Truscreen Group's Book Value per Share for the quarter that ended in Mar. 2024 was NZ$0.01. Hence, Truscreen Group's PB Ratio of today is 3.00.

The historical rank and industry rank for Truscreen Group's PB Ratio or its related term are showing as below:

NZSE:TRU' s PB Ratio Range Over the Past 10 Years
Min: 1.35   Med: 2.8   Max: 8.34
Current: 2.84

During the past 10 years, Truscreen Group's highest PB Ratio was 8.34. The lowest was 1.35. And the median was 2.80.

NZSE:TRU's PB Ratio is ranked worse than
63.22% of 783 companies
in the Medical Devices & Instruments industry
Industry Median: 2.3 vs NZSE:TRU: 2.84

During the past 3 years, the average Book Value Per Share Growth Rate was -41.50% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -38.00% per year.

During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Truscreen Group was -1.80% per year. The lowest was -43.50% per year. And the median was -24.50% per year.

Back to Basics: PB Ratio


Truscreen Group PB Ratio Historical Data

The historical data trend for Truscreen Group's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Truscreen Group PB Ratio Chart

Truscreen Group Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.17 3.18 7.59 4.72 3.67

Truscreen Group Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.59 7.38 4.72 8.14 3.67

Competitive Comparison of Truscreen Group's PB Ratio

For the Medical Devices subindustry, Truscreen Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Truscreen Group's PB Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Truscreen Group's PB Ratio distribution charts can be found below:

* The bar in red indicates where Truscreen Group's PB Ratio falls into.



Truscreen Group PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Truscreen Group's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2024)
=0.018/0.006
=3.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Truscreen Group  (NZSE:TRU) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Truscreen Group PB Ratio Related Terms

Thank you for viewing the detailed overview of Truscreen Group's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Truscreen Group (NZSE:TRU) Business Description

Traded in Other Exchanges
Address
C/- HLB Mann Judd Limited, 57 Symonds Street, Level 6, Equitable House, Grafton, Auckland, NZL, 1010
Truscreen Group Ltd is engaged in providing real-time, accurate detection of pre-cancerous and cancerous cervical cells to help improve the health and well-being of women around the world. The company holds a right to the Truscreen Cervical Cancer screening system which comprises a medical device and process designed to detect the presence in real-time of precancerous and cancerous tissue on the cervix. Its product, Truscreen utilizes technology to detect the pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurements of cervical tissue. The company operates its business in New Zealand, Mexico, China, Russia, Iran, Turkey and others. It has one operating segment, it owns the rights to the Truscreen Cervical Cancer screening device.